

Special Issue

Novel Insights into Depression Research: Neurobiology, Models, Biomarkers and Therapies

Message from the Guest Editor

Depression remains the leading cause of disability worldwide, yet its pathophysiology is still incompletely understood, hampering its diagnosis and therapeutic success. This Special Issue, “Novel Insights into Depression Research: Neurobiology, Models, Biomarkers and Therapies,” highlights breakthroughs that are rapidly redefining this field. We welcome original articles and authoritative reviews that elucidate novel synaptic, immune or gut–brain mechanisms; validate next-generation animal, organoid or in silico models; and identify robust genomic, proteomic or digital biomarkers capable of predicting depression onset, trajectory or treatment response. Contributions showcasing rapid-acting antidepressants and innovative neuromodulation protocols are also welcome, as they further bridge mechanistic insights and clinical practice. We invite researchers to contribute high-quality original research and review articles to this Special Issue that advance our understanding of depression and shape the future of more effective, personalized treatments. We hope that this Special Issue will provide a platform to inform new breakthroughs in this field.

Guest Editor

Prof. Dr. Adela Magdalena Ciobanu

1. Department of Psychiatry “Prof. Dr. Al. Obregia” Clinical Hospital of Psychiatry, Bucharest, Romania
2. Discipline of Psychiatry, Neurosciences Department, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/257899

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).